Archive: Company News
Company News: Curetis´ Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test
— Market authorization paves way for broader Unyvero commercial roll-out in ASEAN region through partner Acumen Research Laboratories
— Near-term clinical validation study of first cartridge-based molecular test for Sepsis Host Response panel licensed from Acumen in preparation
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that Acumen Research Laboratories Pte Ltd. (Acumen), its partner for the commercialization of Unyvero in the ASEAN region, has received approval by the Singapore Health Sciences Authority (HSA) to market the Unyvero HPN Hospitalized Pneumonia Application Cartridge in Singapore.
Company News: Curetis Group: Ares Genetics Receives Funding Commitment for EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017
— Curetis subsidiary Ares Genetics receives funding commitment from Austrian Research Promotion Agency (FFG) for EUR 1.6 million project „The Digital Microbe“
— „The Digital Microbe“ project builds on GEAR platform to develop machine learning tools to combat antibiotic resistances
— Curetis Group announces preliminary, non-audited financial results for 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Ares Genetics GmbH (Vienna, Austria), a wholly-owned subsidiary of Curetis, has received notice from the Austrian Research Promotion Agency (FFG) that it has been awarded a grant for a EUR 1.6 million research project.
Company News: Life Science Inkubator (LSI) Bonn for the first time supports pharma industry spin-out
— Merck spin-off Silvacx receives seed financing of almost EUR 2 million
Life Science Inkubator GmbH (LSI) for the first time supports a research project originating from a pharma company. The project called Silvacx is a spin-off from Merck AG and is developing novel delivery technologies for cancer immunotherapy.
Company News: Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
— Inked new collaboration and commercialization deals with MGI to leverage Curetis´ sample preparation technology
— Enabling short-term commercialization of NGS-based molecular microbiology
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is advancing its strategic alliance in NGS-based infectious disease testing. To this end, Curetis has signed a Supply and Authorization Agreement as well as a further R&D Collaboration and Service Agreement with MGI, a fully-owned subsidiary of BGI Group, one of the world’s leading genome sequencing centers headquartered in Shenzhen, Guangdong, P. R. China.